Form 4: Director Johanna Mercier Exercises NBIX Stock Units

Neurocrine Biosciences Director Johanna Mercier acquired 3,318 shares of common stock through the vesting of restricted stock units.

Summary

• Director Johanna Mercier acquired 3,318 shares of Neurocrine Biosciences (NBIX) common stock.
• The acquisition resulted from the vesting of restricted stock units (RSUs) granted on May 21, 2025.
• The transaction was executed at a price of $0 per share as part of an equity compensation plan.
• Following this transaction, the reporting person holds a total of 6,853 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director equity compensation.

Positives

• Director maintains a direct ownership stake of 6,853 shares in the company.
• The transaction reflects the fulfillment of previously granted equity compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director equity compensation, which is standard practice for publicly traded biotechnology firms to align director interests with shareholder value.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity-based director compensation in the biopharmaceutical sector.
• The use of RSUs as a component of director compensation is consistent with peer companies like Vertex Pharmaceuticals and BioMarin Pharmaceutical.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard equity compensation vesting.

Next Steps

• None mentioned.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Form 4, Insider Trading, Equity Compensation, Director Ownership